This article is more than 5 years old. Information may no longer be current.
Top stories in gastroenterology: Entyvio yields improved patient outcomes, NDA submitted for H. pylori therapy
Click Here to Manage Email Alerts
Among the top stories in gastroenterology last week were study results that suggested changes in how patients are treated with Entyvio since the drug’s approval have led to improvement in inflammatory bowel disease-related outcomes and an announcement that RedHill Biopharma submitted a new drug application to the FDA for Talicia to treat H. pylori infection.
Other highlights included a study that found a single dose of aspirin did not help improve the sensitivity of fecal immunochemical testing for adults undergoing colorectal cancer screening, research that determined fecal microbiota transplantation was safe as a treatment for obesity and a study that found patients with inflammatory bowel disease had higher hospitalization rates for herpes zoster virus compared with other people without IBD.
Better positioning has improved outcomes of Entyvio therapy
Changes in how patients are treated with Entyvio since the drug’s approval have led to improvement in inflammatory bowel disease-related outcomes, according to study results. Read more.
RedHill Biopharma submits NDA for H. pylori therapy
RedHill Biopharma announced that it has submitted a new drug application to the FDA for Talicia to treat H. pylori infection. Read more.
Single-dose aspirin fails to improve fecal immunochemical testing results
A single dose of aspirin did not help improve the sensitivity of fecal immunochemical testing for adults undergoing colorectal cancer screening, according to a study published in JAMA. Read more.
Fecal microbiota transplantation safe in patients with obesity, more research needed
Researchers successfully engrafted microbiota to patients with obesity using stool from lean donors, giving them optimism about the future of fecal microbiota transplantation as a treatment for obesity. Read more.
Patients with inflammatory bowel disease twice as likely to have herpes zoster
Patients with inflammatory bowel disease have higher hospitalization rates for herpes zoster virus compared with other people without IBD, according to study results. Read more.